Roche Holding stock heads into the open after a 0.3% dip
Published on 09/18/2026 at 07:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock closed at 368.60 CHF on SIX Swiss Exchange on September 17, 2026, down 0.3% for the day. According to Swiss blue-chip data, the SMI benchmark index gained 0.57% to finish at 13,947.31 points on the same date, meaning Roche lagged the broader Swiss market despite the modest move.
September 17, 2026 in numbers
Roche Holding AG (ISIN CH0012032048) saw its bearer participation shares trade between an intraday low of 365.20 CHF and a high of 373.20 CHF on September 17, 2026, before settling at 368.60 CHF at the close on SIX Swiss Exchange. Price history over the preceding five sessions shows a prior close of 369.80 CHF on September 16, 2026, implying the 0.3% decline on September 17, 2026 from that level. Trading data from the Swiss order book indicate that multiple closing prints were recorded at 368.60 CHF around 17:31 local time, confirming the session end level.
As Agefi reported on September 17, 2026, the SMI closed 0.57% higher at 13,947.31 points, while Roche’s participation certificate ended the session 0.3% lower, contrasting with gains in other heavyweight constituents. In the same article, Agefi highlighted that Roche shares came under pressure even though the company announced positive clinical results for its Lunsumio regimen in relapsed or refractory follicular lymphoma, underscoring that the market reaction remained muted relative to the fundamental news.
Today’s drivers and events
On September 17, 2026, Roche issued a press release stating that the phase III CELESTIMO study evaluating Lunsumio (mosunetuzumab) in combination with lenalidomide versus MabThera/Rituxan plus lenalidomide in patients with relapsed or refractory follicular lymphoma met its primary endpoint, providing a key clinical milestone that investors continue to digest today ahead of the open. As GlobeNewswire reported on September 17, 2026, Roche also announced the grand opening of its Innovation Center Boston, expanding its United States research footprint in cardiovascular, renal and metabolic diseases, which may shape sentiment on the shares in today’s session. No specific earnings release or shareholder meeting for Roche is scheduled for September 18, 2026 in the available investor communications, so attention today centers on follow-up to these strategic and clinical updates alongside the broader performance of the Swiss equity market.
